Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310197 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1L3MBTL3BIRC2NCF1 | |
| SCHEMBL15933081 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1L3MBTL3BIRC2NCF1 | |
| SCHEMBL25698895 | 0.87 | BIRC2 (0.34) | BIRC2 | |
| SCHEMBL23139621 | 0.87 | BIRC2 (0.34) | BIRC2 | |
| Hydrochloric Acid SCHEMBL25337896 | 0.85 | HPGD (0.34) | ALDH1A1BIRC2 | |
| Hydrochloric Acid SCHEMBL25337894 | 0.85 | HPGD (0.34) | ALDH1A1BIRC2 | |
| SCHEMBL18379008 | 0.84 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1L3MBTL3NCF1 | |
| SCHEMBL14856418 | 0.83 | HTR6 (0.36) | ALDH1A1BIRC2 | |
| SCHEMBL12350484 | 0.83 | HTR6 (0.36) | ALDH1A1BIRC2 | |
| SCHEMBL6582291 | 0.82 | HTR6 (0.39) | BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2016015597-A1 | COMPOUNDS AS CDK SMALL-MOLECULE INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | BET1, EP300, RBBP5 | ALDH1A1 3922/4885L3MBTL1 2394/4885L3MBTL3 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.